Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects.

Next Previous
Search
Trial Profile

Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linezolid (Primary) ; Moxifloxacin
  • Indications Bacterial infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer

    • Most Recent Events

    • 10 Apr 2010 Results assessing QT interval prolongation presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases.
    • 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual initiation date changed from Jan 2009 to Dec 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top